#oncology — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #oncology, aggregated by home.social.
-
https://www.europesays.com/people/236925/ Arm CEO’s AI cancer cure claims come amid pushback over similar ideas #AI #AlphaFold #Anthropic #ArmHoldings #ArtificialIntelligence #astrazeneca #BridgeBio #cancer #CancerTreatment #DrugDevelopment #GoogleDeepMind #healthcare #LawrenceLivermoreNationalLaboratory #medical #oncology #OpenAI #RenéHaas #SamAltman #semiconductors #tech #Technology
-
South China Morning Post: Alibaba open-sources medical AI model that can detect cancer and nearly 150 conditions. “Alibaba Group Holding’s research arm, Damo Academy, has open-sourced an artificial intelligence model capable of identifying nearly 150 abdominal conditions – including cancers – by reading computed tomography (CT) scans, marking the latest step in the firm’s growing […]
https://rbfirehose.com/2026/09/20/south-china-morning-post-alibaba-open-sources-medical-ai-model-that-can-detect-cancer-and-nearly-150-conditions/ -
South China Morning Post: Alibaba open-sources medical AI model that can detect cancer and nearly 150 conditions. “Alibaba Group Holding’s research arm, Damo Academy, has open-sourced an artificial intelligence model capable of identifying nearly 150 abdominal conditions – including cancers – by reading computed tomography (CT) scans, marking the latest step in the firm’s growing […]
https://rbfirehose.com/2026/09/20/south-china-morning-post-alibaba-open-sources-medical-ai-model-that-can-detect-cancer-and-nearly-150-conditions/ -
South China Morning Post: Alibaba open-sources medical AI model that can detect cancer and nearly 150 conditions. “Alibaba Group Holding’s research arm, Damo Academy, has open-sourced an artificial intelligence model capable of identifying nearly 150 abdominal conditions – including cancers – by reading computed tomography (CT) scans, marking the latest step in the firm’s growing […]
https://rbfirehose.com/2026/09/20/south-china-morning-post-alibaba-open-sources-medical-ai-model-that-can-detect-cancer-and-nearly-150-conditions/ -
South China Morning Post: Alibaba open-sources medical AI model that can detect cancer and nearly 150 conditions. “Alibaba Group Holding’s research arm, Damo Academy, has open-sourced an artificial intelligence model capable of identifying nearly 150 abdominal conditions – including cancers – by reading computed tomography (CT) scans, marking the latest step in the firm’s growing […]
https://rbfirehose.com/2026/09/20/south-china-morning-post-alibaba-open-sources-medical-ai-model-that-can-detect-cancer-and-nearly-150-conditions/ -
South China Morning Post: Alibaba open-sources medical AI model that can detect cancer and nearly 150 conditions. “Alibaba Group Holding’s research arm, Damo Academy, has open-sourced an artificial intelligence model capable of identifying nearly 150 abdominal conditions – including cancers – by reading computed tomography (CT) scans, marking the latest step in the firm’s growing […]
https://rbfirehose.com/2026/09/20/south-china-morning-post-alibaba-open-sources-medical-ai-model-that-can-detect-cancer-and-nearly-150-conditions/ -
Bristol Myers Squibb’s global collaboration with Harbour BioMed — including $90M upfront and potential milestones exceeding $1B — highlights sustained momentum around next-generation antibody platforms.
Rather than single assets, pharma companies are increasingly investing in platform technologies designed to address the biological complexity of cancer.
#business #pharma #oncology #investment #biologics #futureofmedicine #innovation
-
Bristol Myers Squibb’s global collaboration with Harbour BioMed — including $90M upfront and potential milestones exceeding $1B — highlights sustained momentum around next-generation antibody platforms.
Rather than single assets, pharma companies are increasingly investing in platform technologies designed to address the biological complexity of cancer.
#business #pharma #oncology #investment #biologics #futureofmedicine #innovation
-
Bristol Myers Squibb’s global collaboration with Harbour BioMed — including $90M upfront and potential milestones exceeding $1B — highlights sustained momentum around next-generation antibody platforms.
Rather than single assets, pharma companies are increasingly investing in platform technologies designed to address the biological complexity of cancer.
#business #pharma #oncology #investment #biologics #futureofmedicine #innovation
-
Bristol Myers Squibb’s global collaboration with Harbour BioMed — including $90M upfront and potential milestones exceeding $1B — highlights sustained momentum around next-generation antibody platforms.
Rather than single assets, pharma companies are increasingly investing in platform technologies designed to address the biological complexity of cancer.
#business #pharma #oncology #investment #biologics #futureofmedicine #innovation
-
Bristol Myers Squibb’s global collaboration with Harbour BioMed — including $90M upfront and potential milestones exceeding $1B — highlights sustained momentum around next-generation antibody platforms.
Rather than single assets, pharma companies are increasingly investing in platform technologies designed to address the biological complexity of cancer.
#business #pharma #oncology #investment #biologics #futureofmedicine #innovation